Saturday 17 October 2026
Export FEMY’s income statement to Excel — free account
Femasys Inc.
FEMY Healthcare Medical Instruments & Supplies
Femasys Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 million, up 40.8% from fiscal 2024. In the quarter to June 2026, revenue fell 18.9%, EPS grew 58.4%, free cash flow grew 11.3% and total debt rose 3,369.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.65
0.09
−5.17%
Follow FEMY
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Jan '20 | Dec '19 | Jan '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 3 | 2 | 2 | 3 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
(10.88) | (17.50) | (5.33) | (5.24) | 3.03 | — | — | — | — | — |
P/S ratio |
9.93 | 15.04 | 14.49 | 8.82 | 22.19 | 10.79 | 10.79 | 10.79 | 10.79 | — |
Altman Z″-Score (non-manufacturers) |
(24.17) | (42.98) | (9.44) | (8.20) | 6.42 | (38.43) | (44.56) | (27.29) | (27.29) | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/Operating CF |
(5.44) | (4.83) | (5.12) | (3.71) | (11.64) | (10.30) | (10.30) | (10.30) | (10.30) | — |
Beneish M-Score |
(2.19) | 0.20 | (3.08) | (2.66) | (2.77) | (3.71) | — | — | — | — |
P/B ratio |
3.88 | 10.63 | 0.85 | 0.70 | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Tangible BV |
3.97 | 10.94 | 0.85 | 0.70 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Sales |
8.20 | 13.00 | (1.68) | (1.81) | 1.32 | 60.75 | 60.75 | 60.75 | 60.75 | — |
EV/EBITDA |
0.00 | 0.00 | 0.13 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(1.01) | (1.09) | 0.16 | 0.20 | (0.20) | (11.04) | (11.04) | (11.04) | (11.04) | — |
EV/FCF |
(0.98) | (1.05) | 0.16 | 0.20 | (0.19) | (11.04) | (11.04) | (11.04) | (11.04) | — |
Quick Ratio |
2.72 | 0.46 | 7.14 | 8.53 | 14.70 | 1.19 | 1.19 | 5.83 | 5.83 | — |
Current Ratio |
4.53 | 0.93 | 7.59 | 9.25 | 15.15 | 1.34 | 1.34 | 6.25 | 6.25 | — |
Net Debt/EBITDA |
0.23 | 0.19 | 1.24 | 1.16 | 3.18 | 0.31 | (9.27) | (4.71) | (4.71) | — |
Debt/Assets |
25.56% | 1.03% | 15.77% | 0.84% | 0.59% | 18.56% | 754.63% | 451.16% | 451.16% | 0.00% |
Debt/Equity |
0.90 | 0.06 | 0.24 | 0.01 | 0.01 | (0.03) | (1.11) | (1.26) | (1.26) | — |
Asset Turnover |
0.14 | 0.08 | 0.05 | 0.05 | 0.07 | 0.14 | 0.10 | 0.07 | 0.15 | — |
Operating CF/Net income |
1.00 | 1.03 | 0.79 | 0.94 | 1.05 | 0.71 | 0.65 | 0.98 | 0.94 | — |
Capex/Depreciation |
(1.54) | (2.56) | (0.30) | (0.73) | (0.52) | (0.05) | 0.00 | 0.00 | 0.00 | — |
Interest Coverage |
(9.30) | (11.09) | (87.72) | (859.28) | (434.21) | (550.25) | (395.05) | (78.23) | (78.23) | — |
| (455.80%) | (182.18%) | (84.82%) | (54.81%) | 59.12% | 13.34% | 14.23% | 24.83% | 24.83% | — | |
| (112.32%) | (93.61%) | (63.81%) | (50.11%) | (41.66%) | (90.91%) | (68.29%) | (89.13%) | (178.27%) | — | |
ROIC |
(578.36%) | 0.00% | (893.46%) | (299.29%) | (303.27%) | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(126.59%) | (1,816.80%) | (67.09%) | (80.89%) | (29.52%) | (246.75%) | (179.15%) | (106.18%) | (106.18%) | — |
Average Days of Receivables |
98.14 | 109.43 | 33.67 | 23.45 | 26.08 | 44.24 | 44.24 | 32.84 | 32.84 | — |
Research and Development Expense of Revenue |
330.43% | 504.36% | 672.45% | 481.99% | 346.22% | 397.98% | 397.98% | 744.18% | 744.18% | — |
Selling, General and Administrative Expense of Revenue |
483.57% | 635.70% | 700.38% | 496.57% | 378.97% | 275.01% | 234.43% | 466.45% | 466.45% | — |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
Share Based Compensation of Revenue |
34.45% | 27.26% | 63.03% | 18.65% | 16.39% | 30.70% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
0.07 | (0.09) | 0.89 | 1.17 | 0.89 | 0.21 | 0.21 | 0.21 | 0.21 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 79.80 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(86.81%) | (77.27%) | (91.09%) | (105.56%) | (67.42%) | (42.02%) | (42.02%) | (42.02%) | (42.02%) | — |
Free Cash Flow Yield |
(84.35%) | (82.49%) | (73.53%) | (104.75%) | (31.47%) | (50.98%) | (50.98%) | (50.98%) | (50.98%) | — |
Revenue per Share |
1.16 | 1.46 | 1.39 | 2.04 | 3.52 | 21.62 | 0.00 | 0.08 | 0.00 | — |
Operating CF per Share |
(9.45) | (17.46) | (14.67) | (18.17) | (23.63) | (102.77) | 0.00 | (0.94) | 0.00 | — |
Capex per Share |
(0.27) | (0.68) | (0.19) | (0.69) | (0.91) | (0.66) | 0.00 | 0.00 | 0.00 | — |
Free Cash Flow per Share |
(9.72) | (18.15) | (14.85) | (18.85) | (24.55) | (103.43) | 0.00 | (0.94) | 0.00 | — |
Cash per Share |
4.69 | 3.10 | 28.23 | 21.94 | 73.85 | 69.21 | 0.00 | 0.63 | 0.00 | — |
Shareholders Equity per Share |
2.97 | 2.07 | 23.86 | 25.80 | 78.46 | (1,079.49) | 0.00 | (3.86) | 0.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
2.97 | 2.07 | 23.86 | 25.80 | 78.46 | (1,079.49) | 0.00 | (3.86) | 0.00 | — |
Free Cash Flow |
(19.22) | (20.21) | (11.42) | (11.14) | (8.24) | (4.96) | (4.49) | (11.01) | (10.55) | — |
Working Capital |
12.82 | (0.56) | 20.12 | 12.60 | 23.94 | 0.97 | 0.97 | 6.75 | 6.75 | — |
Capital Expenditures |
(0.52) | (0.76) | (0.14) | (0.41) | (0.31) | (0.03) | (0.03) | (0.70) | (0.70) | — |
Net Current Asset Value |
1.60 | (2.12) | 13.77 | 12.48 | 23.39 | (55.56) | (55.56) | (49.98) | (49.98) | — |
EV/EBIT |
0.00 | 0.00 | 0.12 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.23 | 0.47 | 0.13 | 0.34 | 0.26 | 0.03 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.18 | 0.19 | 0.44 | 0.38 | 0.37 | 0.37 | 0.38 | 0.28 | 0.28 | — |
Cash ROIC |
(94.04%) | (343.38%) | (25.70%) | (39.30%) | (16.06%) | 10.54% | (50.39%) | (57.63%) | (55.25%) | — |
Accounts Receivable Turnover |
4.15 | 5.55 | 12.15 | 14.91 | 11.23 | 8.25 | 9.91 | 11.11 | 11.11 | — |
Accounts Payable Turnover |
0.54 | 0.43 | 0.46 | 0.92 | 0.66 | 0.43 | 2.28 | 2.78 | 2.78 | — |
Inventory Turnover |
0.20 | 0.29 | 0.69 | 1.37 | 2.18 | 2.06 | 8.30 | 8.50 | 8.50 | — |
Average Days of Payables |
765.69 | 950.51 | 1,092.60 | 421.91 | 439.01 | 803.00 | 195.84 | 133.20 | 129.35 | — |
Days of Inventory on Hand |
2,401.62 | 2,040.56 | 640.60 | 360.70 | 205.26 | 156.48 | 43.24 | 47.76 | 38.15 | — |
Average Receivables |
0.55 | 0.29 | 0.09 | 0.08 | 0.11 | 0.13 | 0.10 | 0.08 | 0.08 | — |
Average Payables |
1.62 | 1.28 | 0.82 | 0.48 | 0.56 | 0.71 | 0.62 | 0.47 | 0.47 | — |
Average Inventory |
4.39 | 1.86 | 0.55 | 0.32 | 0.17 | 0.15 | 0.17 | 0.16 | 0.16 | — |
Average Assets |
16.58 | 20.10 | 22.33 | 22.74 | 18.09 | 7.61 | 10.13 | 12.65 | 6.32 | — |
Average Common Equity |
4.09 | 10.33 | 16.80 | 20.79 | (12.75) | (51.83) | (48.61) | (45.39) | (45.39) | — |
Columns are period end dates